Advertisement

MiR-let-7d-3p regulates IL-17 expression through targeting AKT1/mTOR signaling in CD4+ T cells

  • Jian Wang
  • Xin Wang
  • Longfei Wang
  • Chao Sun
  • Changhao Xie
  • Zhijun LiEmail author
Article
  • 29 Downloads

Abstract

The aberrant expression of interleukin-17 (IL-17) has been reported in the pathogenesis of autoimmune diseases, such as primary Sjögren’s syndrome (pSS). However, the detailed mechanism remains poorly understood. We aim to characterize the expression of IL-17 in pSS and analyze the detailed underlying mechanism. IL-17 and microRNA miR-let-7d-3p expression were assayed by quantitative real-time PCR and Western blot, and proliferation-related protein expression was measured by Western blot. Luciferase reporter assays were performed to detect the direct regulation of IL-17 by miR-let-7d-3p. Expression of miR-let-7d-3p was negatively correlated with the expression of IL-17 in patients with pSS. Besides, the AKT1/mTOR signaling pathway was found critical for miR-let-7d-3p-mediated IL-17 expression. Furthermore, miR-let-7d-3p targeted AKT1 to bridge the regulation of IL-17. Finally, we verified AKT1 co-expression could rescue IL-17 downregulation caused by miR-let-7d-3p. Our study revealed novel mechanism that how did IL-17 was exactly modulated by miR-let-7d-3p and the potential of miR-let-7d-3p-AKT1-mTOR-IL-17 signaling as therapeutic targets for autoimmune diseases.

Keywords

Interleukin-17 Primary Sjögren’s syndrome miR-let-7d-3p AKT1 mTOR 

Notes

Acknowledgments

We thank the Affiliated Hospital to Bengbu Medical college for the capital and equipment support.

Author contributions

Jian Wang, Xin Wang, and Longfei Wang performed the experiments. Jian Wang, Xin Wang, and Zhijun Li analyzed data. Longfei Wang, Chao Sun, Changhao Xie, and Zhijun Li contributed reagents/materials/analysis tools. Jian Wang, Xin Wang, and Zhijun Li wrote the manuscript. All authors discussed the results and commented on the manuscript.

Funding information

This work was supported by the Nature Science Key Program of Bengbu Medical College (no. BYKY1852ZD).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Asam S, Neag G, Berardicurti O, Gardner D, Barone F (2019) The role of stroma and epithelial cells in primary Sjogren’s syndrome. Rheumatology (Oxford).  https://doi.org/10.1093/rheumatology/kez050
  2. Avendaño C, Menéndez JC (2008) Medicinal chemistry of anticancer drugs, 1st edn. ElsevierGoogle Scholar
  3. Didiano D, Hobert O (2008) Molecular architecture of a miRNA-regulated 3' UTR. RNA 14:1297–1317.  https://doi.org/10.1261/rna.1082708 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Fang Z, Rajewsky N (2011) The impact of miRNA target sites in coding sequences and in 3'UTRs. PLoS One 6:e18067.  https://doi.org/10.1371/journal.pone.0018067 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L (2019) The pipeline of targeted therapies under clinical development for primary Sjogren’s syndrome: a systematic review of trials. Autoimmun Rev.  https://doi.org/10.1016/j.autrev.2018.12.008 CrossRefGoogle Scholar
  6. Furuzawa-Carballeda J, Sánchez-Guerrero J, Betanzos JL, Enriquez AB, Avila-Casado C, Llorente L, Hernández-Molina G (2014) Differential cytokine expression and regulatory cells in patients with primary and secondary Sjogren’s syndrome. Scand J Immunol 80:432–440.  https://doi.org/10.1111/sji.12224 CrossRefPubMedGoogle Scholar
  7. Gallo A et al (2019) miRNA-mediated regulation of mucin-type O-glycosylation pathway: a putative mechanism of salivary gland dysfunction in Sjogren’s syndrome. J Rheumatol.  https://doi.org/10.3899/jrheum.180549 CrossRefGoogle Scholar
  8. Goules AV, Kapsogeorgou EK, Tzioufas AG (2017) Insight into pathogenesis of Sjogren’s syndrome: dissection on autoimmune infiltrates and epithelial cells. Clin Immunol 182:30–40.  https://doi.org/10.1016/j.clim.2017.03.007 CrossRefPubMedGoogle Scholar
  9. Jin W, Dong C (2013) IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2:e60.  https://doi.org/10.1038/emi.2013.58 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM (2009) Systemic and local interleukin-17 and linked cytokines associated with Sjogren’s syndrome immunopathogenesis. Am J Pathol 175:1167–1177.  https://doi.org/10.2353/ajpath.2009.090319 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Kim JS et al (2013) Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol 14:611–618.  https://doi.org/10.1038/ni.2607 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Koga T, Ichinose K, Kawakami A, Tsokos GC (2019) The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Rev Clin Immunol 1–9.  https://doi.org/10.1080/1744666X.2019.1593141 CrossRefGoogle Scholar
  13. Kolenda T, Przybyla W, Teresiak A, Mackiewicz A, Lamperska KM (2014) The mystery of let-7d—a small RNA with great power. Contemp Oncol (Pozn) 18:293–301.  https://doi.org/10.5114/wo.2014.44467 CrossRefGoogle Scholar
  14. Kurebayashi Y et al (2012) PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORgamma. Cell Rep 1:360–373.  https://doi.org/10.1016/j.celrep.2012.02.007 CrossRefPubMedGoogle Scholar
  15. Lin X et al (2015) Th17 cells play a critical role in the development of experimental Sjogren’s syndrome. Ann Rheum Dis 74:1302–1310.  https://doi.org/10.1136/annrheumdis-2013-204584 CrossRefPubMedGoogle Scholar
  16. Matsui K, Sano H (2017) T helper 17 cells in primary Sjogren’s syndrome. J Clin Med 6.  https://doi.org/10.3390/jcm6070065 CrossRefGoogle Scholar
  17. Mavragani CP, Nezos A, Moutsopoulos HM (2013) New advances in the classification, pathogenesis and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 25:623–629.  https://doi.org/10.1097/BOR.0b013e328363eaa5 CrossRefPubMedGoogle Scholar
  18. Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjogren’s syndrome. Nat Rev Rheumatol 9:544–556.  https://doi.org/10.1038/nrrheum.2013.110 CrossRefPubMedGoogle Scholar
  19. Okoye IS, Wilson MS (2011) CD4+ T helper 2 cells—microbial triggers, differentiation requirements and effector functions. Immunology 134:368–377.  https://doi.org/10.1111/j.1365-2567.2011.03497.x CrossRefPubMedPubMedCentralGoogle Scholar
  20. Pekel G et al (2019) Evaluation of corneal layers and anterior sclera in patients with primary Sjogren’s syndrome. Arq Bras Oftalmol.  https://doi.org/10.5935/0004-2749.20190054
  21. Reksten TR, Johnsen SJ, Jonsson MV, Omdal R, Brun JG, Theander E, Eriksson P, Wahren-Herlenius M, Jonsson R, Nordmark G (2014) Genetic associations to germinal centre formation in primary Sjogren’s syndrome. Ann Rheum Dis 73:1253–1258.  https://doi.org/10.1136/annrheumdis-2012-202500 CrossRefPubMedGoogle Scholar
  22. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S (2008) Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 181:2898–2906CrossRefGoogle Scholar
  23. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R (2002) Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 169:642–646CrossRefGoogle Scholar
  24. Szodoray P et al (2005) Distinct profiles of Sjogren’s syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117:168–176.  https://doi.org/10.1016/j.clim.2005.06.016 CrossRefPubMedGoogle Scholar
  25. Talotta R et al (2019) Evaluation of salivary and plasma microRNA expression in patients with Sjogren’s syndrome, and correlations with clinical and ultrasonographic outcomes. Clin Exp Rheumatol 37. Suppl 118 (2019): S70–77.Google Scholar
  26. Wang-Renault SF, Boudaoud S, Nocturne G, Roche E, Sigrist N, Daviaud C, Bugge Tinggaard A, Renault V, Deleuze JF, Mariette X, Tost J (2018) Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjogren’s syndrome. Ann Rheum Dis 77:133–140.  https://doi.org/10.1136/annrheumdis-2017-211417 CrossRefPubMedGoogle Scholar
  27. Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H (2018) Expression of interleukin-17 in primary Sjogren’s syndrome and the correlation with disease severity: a systematic review and meta-analysis. Scand J Immunol 87:e12649.  https://doi.org/10.1111/sji.12649 CrossRefPubMedGoogle Scholar
  28. Zheng M, Hou L, Ma Y, Zhou L, Wang F, Cheng B, Wang W, Lu B, Liu P, Lu W, Lu Y (2019) Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer 18:76.  https://doi.org/10.1186/s12943-019-0999-x CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2019

Authors and Affiliations

  • Jian Wang
    • 1
  • Xin Wang
    • 1
  • Longfei Wang
    • 2
  • Chao Sun
    • 1
  • Changhao Xie
    • 1
  • Zhijun Li
    • 1
    Email author
  1. 1.Department of Rheumatology and Immunologythe First Affiliated Hospital to Bengbu Medical CollegeBengbuChina
  2. 2.Department of Pathology, ZhongDa HospitalSoutheast UniversityNanjingChina

Personalised recommendations